Coronary artery disease is the leading cause of death in developed countries1 – but diagnostic methods for this disease have remained unchanged for nearly 50 years.
Artrya is an AI-driven MedTech company, founded in 2019, and brought to life in Perth, Australia. Artrya was co-founded by John Konstantopoulos and John Barrington AM, who came together with a mutual passion for disruptive technologies and improving health outcomes across the globe. Artrya sees heart disease in a new way, using data-driven solutions to assist physicians with cardiovascular diagnosis.
Our innovative diagnostic support solution, Artrya Salix, accurately assesses and detects plaque features, in real-time, without the need for invasive interventions.
Traditional diagnostic processes for coronary artery disease have avoided sophisticated analysis because it was time-consuming and required significant manual inputs. At Artrya, we’re paving the way for a diagnostic process that is better for patients, more effective for healthcare professionals and more efficient for healthcare systems.
Ar-tree-a (phonetic) Artrya is a play on the word ‘artery,’ the vessel which takes oxygen-rich blood from the heart to other parts of the body.
The word artery is based on the Greek word aρτηρiα (arteria), meaning air and to keep.
This meaning underpins our mission to use advanced, AI-based technology to reduce the number of heart attacks that occur around the world each year and, fundamentally, save lives.
References: